Home > About us > Company History

Company History

1997

»Founded as a spin-off from the Idar-Oberstein based Bone Marrow Transplantation Unit

1999

»Granted a first Manufacturing licence from the local authorities for the production of bone marrow
and apheresis stem cell products as well as cord blood preparations

»Since then manufacturing and quality control of stem cell products (bone marrow, apheresis, cord blood)

2000

»Manufacturing licence is extended to cover the production of diverse retroviral vectors and genetically
modified CD34+ stem cells

2001

»EUFETS becomes a subsidiary of Fresenius Biotech GmbH

»EUFETS decides to build new clean room facility

»Manufacturing licence is extended to cover the production of diverse retroviral vectors and genetically
modified T-cells

2002

»EUFETS supports first clinical trial with retroviral vector and allogeneic gene-modified T-cells (suicide
gene therapy)

»EUFETS performs first GLP studies

2003

»EUFETS achieves accreditation as Good Laboratory Practice (GLP) facility

»New production facility is inspected and accepted by the local authorities for the production of cell- and
gene therapy medicinal products

»EUFETS produces retroviral vector for ADA SCID gene therapy trial in UK

2004

»Manufacturing licence is extended to cover the production of genetically modified HIV+ T-cells as well
as several new retroviral vectors

»EUFETS produces study medication for a phase I/II anti HIV gene therapy (autologous T-cell) trial

»EUFETS produces gene-modified autologous stem cells for a phase I/II CGD gene therapy trial

»EUFETS produces retroviral vector for several clinical gene therapy trials in Europe

2005

»New large scale GMP production technique for retroviral vectors and subsequent concentration is
established and validated

»Manufacturing licence is extended to cover the new production techniques for retroviral vector production

»EUFETS produces retroviral vector for several clinical gene therapy trials in Europe and Japan

2006

»EUFETS produces gene-modified autologous stem cells for the first gene therapy trial in WAS

»First production of retroviral vectors for Australian customer

»Production of first concentrated vector batch for clinical use

2009

»EUFETS becomes a subsidiary of BioNTech AG, Mainz